Gentherapie des Prostatakarzinoms

Allogeneic retrovirally transduced, IL‐2‐ and IFN‐γ‐secreting cancer cell vaccine in patients with hormone refractory prostate cancer—a phase I clinical trial

“…Although it is too early to draw conclusions, encouraging results have been obtained in some cases, and lessons have been learned in others 37–39. Gene therapy against PCa has been approached with many different treatment modalities, as reviewed recently 40–44. Some published reports have revealed encouraging results with respect to PSA changes and other parameters such as CD8 + T lymphocyte infiltration into established local recurrences of PCa 45–47.…”